Johnson & Johnson stands alone as a leader across major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.
J&J's strong position in oncology (Darzalex and Carvykti) and next-generation immunology product Tremfya (following Stelara) create a foundation of innovative drugs.
J&J's late-stage drug pipeline could face significant competitive threats, as oncology and immunology remain popular areas for biopharma investment.
|
Metric
|
JNJ
|
ABBV
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.66 | 24.02 | 17.30 |
Price/Book Value | 7.52 | — | 7.45 |
Price/Sales | 6.41 | 6.91 | 5.15 |
Price/Cash Flow | 20.75 | 18.93 | 14.75 |
|
Metric
|
JNJ
|
ABBV
|
NVS
|
|---|---|---|---|
Quick Ratio | 0.77 | 0.52 | 0.53 |
Current Ratio | 1.03 | 0.80 | 0.85 |
Interest Coverage | 24.09 | 2.96 | 13.66 |
|
Metric
|
JNJ
|
ABBV
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | 13.33% | 13.37% | 15.46% |
Return on Equity (Normalized) | 32.77% | — | 39.95% |
Return on Invested Capital (Normalized) | 20.14% | 29.17% | 22.43% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|D^@C<BR | LOCK|^Dy | $1T | |||
| AbbVie Inc
ABBV
| LOCK|N^gHL^ | LOCK|xJQ | $432B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|L<h&C@x | LOCK|#WQ | $320B | |||
| Merck & Co Inc
MRK
| LOCK|KPLzn> | LOCK|gv% | $298B | |||
| Novartis AG ADR
NVS
| LOCK|HYv$r?? | LOCK|M! | $287B | |||
| AstraZeneca PLC
AZN
| LOCK|WXMfg!& | LOCK|?^S | $256B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|>$FXc#R | LOCK|ZWs | $215B | |||
| Amgen Inc
AMGN
| LOCK|x^s@@$g | LOCK|j<t | $192B | |||
| Gilead Sciences Inc
GILD
| LOCK|GLWV^c# | LOCK|tG$ | $161B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States